Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 -11.46 (-4.96%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

September 29, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

September 02, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

August 30, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals, Inc. Investors: Investigation Launched Into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by Kessler Topaz Meltzer & Check, LLP

August 24, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

August 24, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP

August 20, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

August 20, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

August 19, 2026

From Kirby McInerney LLP

Via Business Wire

NASDAQ: ALNY: Kessler Topaz Meltzer & Check, LLP Launches Investigation Into Alnylam Pharmaceuticals, Inc.

August 19, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ALNY ALERT: Investigation Launched Into Alnylam Pharmaceuticals, Inc., Investors Are Encouraged to Contact KTMC Law Firm

August 18, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ALNY Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

August 17, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

August 14, 2026

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

August 04, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

August 03, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

July 30, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 30, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

July 30, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

July 30, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

July 16, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

July 15, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

June 12, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

June 03, 2026

From Alnylam Pharmaceuticals, Inc. and Inceptive

Via Business Wire

Alnylam Issues 2025 Corporate Responsibility Report

May 19, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

May 12, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming Investor Conferences

May 07, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

May 04, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

April 30, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation

April 20, 2026

Via Investor Brand Network

Topics Artificial Intelligence

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

Via Investor Brand Network

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

From BioMedWire

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.